In the migraine marketing wars, AbbVie just lobbed an ace: The Ubrelvy maker announced tennis phenom and migraine sufferer Serena Williams is its new spokesperson. Williams uses Ubrelvy to stop acute ...

Ubrelvy (ubrogepant) and Nurtec ODT (rimegepant) are prescription drugs used to treat migraine episodes. Ubrelvy comes as a tablet that you swallow. Nurtec ODT comes as a tablet that dissolves on or ...

Biohaven Pharmaceuticals is showing its migraine med Nurtec ODT can hold its own against Goliath competition from AbbVie's Ubrelvy. Biohaven reported on Monday that its oral CGRP med now tops AbbVie’s ...

The Food and Drug Administration (FDA) has recently intervened regarding a migraine medication advertisement featuring tennis superstar Serena Williams. The FDA’s concerns center around claims that ...

Ubrelvy (ubrogepant) is a brand-name prescription drug used to treat migraine episodes. It is a type of drug called a calcitonin gene-related peptide (CGRP) antagonist. If a person has a Medicare Part ...

Over the years, Olympic gold medalist Aly Raisman has been a vocal mental health advocate. While she is certainly not moving away from that role anytime soon, she’s now ready to discuss her migraine ...

The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of ...

Please provide your email address to receive an email when new articles are posted on . Reyvow, Nurtec ODT and Ubrelvy were less efficacious than triptans for treating migraines, but these new ...

For years, Laura could count on having debilitating migraine attacks a handful of times per month without fail. Their frequency would increase during months when she was especially stressed or ...

Allergan’s Ubrelvy (ubrogepant) has won clearance in the US for the treatment of acute treatment of migraine in adults, with or without aura. The decision makes Ubrelvy the first oral CGRP receptor ...

The FDA approved Allergan's Ubrelvy treatment for migraines this week. The drugmaker reported that the oral drug demonstrated "clinically significant pain relief" within two hours. The ubrogepant ...